Versanis wants to compete with Lily and Novo in weight loss space

Weight loss concept

Versanis Bio, a clinical-stage biopharmacy company based in New York, publication The results of the pooled analysis show that its key asset, bimagrumab, improves body composition in both diabetic and non-diabetic patients.

Findings obtained by pooling data from five previously completed Phase II trials show that 24-week intravenous baimaglumab treatment at the highest dose allocation reduced total fat mass in non-diabetic participants by 14.6%. I showed that I was connected. By comparison, patients receiving placebo had a 2.4% increase in fat mass.

The beneficial effects of Bimagrumab were even stronger among diabetics with a 16.5% decrease in body fat, while the placebo comparator showed a 0.8% increase. Fat loss persisted and improved, with diabetics reporting a 20.5% reduction in fat mass by week 48. Apart from fat loss, baimaglumab treatment also improved lean body mass in these patients by 3.6%.

The results of these findings will be presented by Dr. Lloyd Klickstein, Director of Versanis, during the “RapidFire” poster session at the 2022 Endocrine Society Annual Meeting and Expo (ENDO).

“This analysis further highlights the potential of obese patients to change their lives by adding a unique function of increasing muscle mass, allowing for significant fat loss and significantly improving body composition. “We do,” Klickstein said in a statement. “Furthermore, unlike other existing obesity treatments, baimaglumab shows similar activity in both diabetic and non-diabetic patients.”

Bimagrumab, the first activin type II receptor monoclonal antibody in its class, represents Versanis’ attempt to enter the highly competitive weight loss market and potentially transform. Previously evaluated as a treatment for a variety of muscle wasting indications, baimaglumab is now being tested as a way to reduce body fat, especially abdominal visceral fat, while at the same time improving muscle mass.

The Versanis investigational drug is scheduled for Phase IIb trials later this year to evaluate its safety and efficacy in obese non-diabetic participants. By testing vimaglumab as monotherapy and in combination with incretin agonists, Phase IIb trials aim to determine whether vimaglumab can induce substantial weight loss without compromising muscle mass. is.

“Incretin therapy has been shown to promote weight loss, but at the expense of significant lean body mass loss,” Klickstein said. “We believe that co-administration of Bimaglumab can prevent this unwanted effect while amplifying the overall fat loss.”

However, as obese drag racing intensifies, bimagrumab faces fierce competition. In the 2022 ADA Science Session Eli Lilly reveals results From a phase I mechanism of action study showing that the injectable drug Munjaro reduces weight and fat mass in adults with type 2 diabetes and is even better. Novo NordiskSemaglutide.

In addition, at ADA, several post-hoc and follow-up analyzes of the Global SURPASS enrollment program further strengthen Mounjaro’s position alongside established weight-loss medications to help adult diabetics reach both weight and A1C goals. It was shown to have helped.

Meanwhile, other obesity-related drugs attracted attention at the Boston-based ENDO. Rhythm medicine revealed The company’s setomeranotide was able to induce, as well as maintain, weight loss in severely obese patients caused by Bardet-Biedle syndrome or POMC or LEPR deficiency.

“Our response to precision treatment has been shown to be sustained, and both adult and pediatric patients are experiencing a continuous decline in weight-related measurements through long-term prolongation,” Rhythm. Said David Meaker, MD, Chairman and Chief Executive Officer of. He said in a statement. “This supports our belief in cetomeranotide as a chronic therapy throughout the indications at the approval or registration stage.”


Leave a Comment